RPL9

Across TCGA pan-cancer cohorts, RPL9 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RPL9 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPL9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and UCEC are the cancer types where RPL9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.954	0.646	<.001	41	view →
LUAD	DFS	Median	All	0.759	0.499	.002	20	view →
UCEC	OS	Tertile	II,III,IV	0.519	1.000	.018	16	view →
CCRCC	OS	Quartile	All	0.554	1.000	.008	13	view →
PDAC	DFS	Median	III,IV	0.433	0.797	.010	12	view →
OV	DFS	Median	All	0.869	1.000	.035	4	view →
GBM	DFS	Median	All	0.288	0.459	.023	3	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPL9–HNSC (DFS)

Open the HNSC breakdown →